Abiomed Inc (NASDAQ:ABMD) Institutional Investors Sentiment Falls in Q4 2017

May 17, 2018 - By Margaret Downey

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Sentiment for Abiomed Inc (NASDAQ:ABMD)

Abiomed Inc (NASDAQ:ABMD) institutional sentiment decreased to 1.18 in Q4 2017. Its down -0.12, from 1.3 in 2017Q3. The ratio is negative, as 152 investment managers increased or started new equity positions, while 129 decreased and sold positions in Abiomed Inc. The investment managers in our partner’s database now possess: 36.44 million shares, down from 38.51 million shares in 2017Q3. Also, the number of investment managers holding Abiomed Inc in their top 10 equity positions decreased from 10 to 5 for a decrease of 5. Sold All: 19 Reduced: 110 Increased: 97 New Position: 55.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $16.88 billion. It also provides continuum of care to heart failure patients. It has a 190.84 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

The stock decreased 0.43% or $1.63 during the last trading session, reaching $380.34. About 410,878 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since May 17, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on July, 26. They expect $0.80 earnings per share, up 77.78 % or $0.35 from last year’s $0.45 per share. ABMD’s profit will be $35.50 million for 118.86 P/E if the $0.80 EPS becomes a reality. After $0.80 actual earnings per share reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Palo Alto Investors Llc holds 12.8% of its portfolio in ABIOMED, Inc. for 1.59 million shares. Shaker Investments Llc Oh owns 28,233 shares or 3.5% of their US portfolio. Moreover, Biondo Investment Advisors Llc has 3.3% invested in the company for 69,794 shares. The Maryland-based Brown Capital Management Llc has invested 3.25% in the stock. Hamilton Lane Advisors Llc, a Pennsylvania-based fund reported 23,241 shares.

Since January 1, 0001, it had 0 insider purchases, and 5 insider sales for $31.65 million activity.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Ratings analysis reveals 88% of Abiomed’s analysts are positive. Out of 8 Wall Street analysts rating Abiomed, 7 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $220.0 while the high is $370.0. The stock’s average target of $312.75 is -17.77% below today’s ($380.34) share price. ABMD was included in 12 notes of analysts from December 21, 2017. The rating was maintained by SunTrust with “Buy” on Friday, February 16. Piper Jaffray maintained ABIOMED, Inc. (NASDAQ:ABMD) on Thursday, January 4 with “Buy” rating. Morgan Stanley maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Friday, February 2. Morgan Stanley has “Equal-Weight” rating and $259 target. On Monday, April 9 the stock rating was maintained by Stephens with “Buy”. Stephens maintained ABIOMED, Inc. (NASDAQ:ABMD) on Friday, February 2 with “Buy” rating. As per Tuesday, May 1, the company rating was maintained by Morgan Stanley. As per Thursday, February 1, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by Jefferies given on Thursday, December 21. The rating was maintained by Guggenheim with “Buy” on Friday, February 2. On Thursday, February 1 the stock rating was maintained by Jefferies with “Buy”.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018, also Nasdaq.com with their article: “Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33 …” published on May 03, 2018, Seekingalpha.com published: “ABIOMED (ABMD) Q4 2018 Results – Earnings Call Transcript” on May 03, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Benzinga.com and their article: “Abiomed Earnings Outlook” published on May 02, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” with publication date: May 11, 2018.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: